Dr. Kiyuk Chang, from Seoul St. Mary’s Hospital, discusses the results of the TALOS-AMI trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that de-escalating stabilized acute myocardial infarction patients from high-potency dual antiplatelet therapy with ticagrelor to a lower-potency option – clopidogrel – 30 days after percutaneous coronary intervention was safer and more effective than continuing on ticagrelor beyond 30 days.